Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Phreesia, Inc.
PHR
NYSE·Healthcare·Medical - Healthcare Information Services·Mkt cap $662.6M
$10.94
▲ +2.05%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$7.77 - $32.76
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 63.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Integrated platform combining intake, payments, and clinical workflows reduces vendor fragmentation
- Multi-modal deployment (mobile, web, kiosks) provides flexibility and broad market reach
- Recurring SaaS revenue model with high customer switching costs and sticky relationships
- Extensive healthcare specialization expertise across 25+ clinical specialties
- Embedded payment processing creates additional revenue streams and customer lock-in
Bear Case
1 risk
- Average volatility.
Growth
Moderate growth ahead
Digital transformation acceleration in healthcare post-COVID-19
Value
Fairly valued vs Healthcare IT & Services peers
Momentum
Hot
+28.1% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying PHR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 3, 2026
MAY 27, 2026
Reported EPS of $0.05 vs $0.02 consensus (+150.0% surprise). Revenue of $130.9M vs $130.1M expected (+0.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+150.0%
Next: Sep 3, 2026
Revenue trend · last 8Q
—
—
—
+15%
+15%
+15%
+13%
+16%
Q1 24
Q2 24
Q3 24
Q4 25
Q1 25
Q2 25
Q3 25
Q4 26
$101.2M
$102.1M
$106.8M
$109.7M
$115.9M
$117.3M
$120.3M
$127.1M
Margins · last 8Q
Gross
43.0%
Operating
-4.4%
Profit
1.0%
Wall Street consensus
14 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
50%
Sell
0%
Median Price Target
$12.00
▲ +9.7% vs $10.94
Latest: Truist · $12.00 · May 29, 2026
6 analysts covering